StockIQpro
NASDAQ:KYMR

Kymera Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Kymera Therapeutics, Inc.'s revenue fell 16.7% in fiscal 2025 to $39.2M while operating margin fell to −891.1%. Free cash flow was −$234.3M, −597.6% of revenue, and the diluted share count rose 12.6%.Summary generated from Kymera Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$39.2M
Revenue growth−16.7%
Revenue, 5-yr CAGR+2.9%
Gross margin0.0%
Operating margin−891.1%
Net margin−794.0%
ROICn/a
Return on equity−25.8%
Debt / equityn/a
Free cash flow−$234.3M
FCF margin−597.6%
Share count change+12.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue7347794739
Operating income−101−161−166−262−349
Net income−100−155−147−224−311
Free cash flow−131−156−137−207−234

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)